Evidence map›Paper›PMID 42420629›Full record

Trial reportBritish journal of cancer2026

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Katrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, Ksenija Nesic, Sally Baron-Hay, Sumitra Ananda, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Nick Murray and 18 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Katrin M SjoquistNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia. Katrin.sjoquist@sydney.edu.au.ORCID http://orcid.org/0000-0001-9028-8682
Alexander DobrovicDepartment of Surgery, The University of Melbourne, Parkville, Australia.
Kristy P RobledoNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.
Ksenija NesicWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Sally Baron-HayRoyal North Shore Hospital, Sydney, Australia.ORCID http://orcid.org/0000-0002-9748-1458
Sumitra AnandaAustralia New Zealand Gynaecological Oncology Group, Sydney, Australia.
Nicole McCarthyBreast Cancer Trials ANZ, Newcastle, Australia.
Jeffrey GohAustralia New Zealand Gynaecological Oncology Group, Sydney, Australia.
Christopher SteerBorder Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, Albury, Australia.
Nick MurrayBreast Cancer Trials ANZ, Newcastle, Australia.
Sonia YipNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.
Linda R MileshkinAustralia New Zealand Gynaecological Oncology Group, Sydney, Australia.ORCID http://orcid.org/0000-0001-6826-6014
J Lynn FinkXING Genomic Services, Brisbane, Australia.
Garry ChangNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.
Lisa BaileyNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.
Yvonne LeeNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.
Danka S ZebicNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.ORCID http://orcid.org/0000-0001-9370-3722
U G Imalki U KariyawasamWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID http://orcid.org/0000-0003-3540-8607
Kristy Shield-ArtinWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID http://orcid.org/0000-0002-3969-9846
Andrew JarrattWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Justin BedőWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID http://orcid.org/0000-0001-5704-0212
Anthony T PapenfussWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Olga KondrashovaWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID http://orcid.org/0000-0003-0022-5149
Matthew J WakefieldWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID http://orcid.org/0000-0001-6624-4698
Cassandra J VandenbergWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.ORCID http://orcid.org/0000-0002-8891-8873
Martin R StocklerNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.ORCID http://orcid.org/0000-0003-3793-8724
Clare L Scott *Australia New Zealand Gynaecological Oncology Group, Sydney, Australia.
Paul M Waring *XING Genomic Services, Brisbane, Australia.

Funding

National Breast Cancer Foundation (NBCF) PS-15-048
6 · The paper itself

Abstract

backgroundHomologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (meBRCA1) or RAD51C (meRAD51C) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD.

methodsSingle-arm phase 2 trial of olaparib 300 mg orally twice daily. Tumour meBRCA1/meRAD51C determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing. PRIMARY OUTCOME: objective tumour response rate (OTRR) at 6 months(m). SECONDARY OUTCOMES: progression-free survival (PFS), OTRR according to HR gene aberration, and safety.

resultsTotal 22 enrolled: promoter methylation detected in 8/15 HGSOC and 5/7 TNBC, and pathogenic variants (PV) in non-BRCA HR genes. OTRR at 6 m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6 m/12 m PFS were 53% / 25% (HGSOC), and 17% / 0% (TNBC).

conclusionsOlaparib demonstrated activity in HGSOC beyond gBRCAm, including with meBRCA1 or gRAD51C PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on meBRCA1/meRAD51C require exploration to improve patient selection for PARPi. CLINICAL TRIALS REGISTRATION: Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.

Indexed as

Ovarian NeoplasmsPhthalazinesPiperazinesTriple Negative Breast NeoplasmsAdultAgedBRCA1 ProteinBRCA2 ProteinDNA MethylationFemaleGerm-Line MutationHomologous RecombinationHumansMiddle AgedNeoplasm Recurrence, LocalPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID42420629
PMCPMC13578435

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.